Podcast: Play in new window | Download | Embed
Subscribe: Apple Podcasts | Spotify | Amazon Music | Android | RSS
Dry eye disease is no longer viewed as a simple problem solved with artificial tears. As Dr. Laura Periman explains, modern research is redefining dry eye as a complex, multifactorial disease that requires personalized diagnosis and targeted treatment. During her conversation on The 20/20 Podcast, she explores how innovations in molecular medicine, neuroscience, and ocular surface diagnostics are reshaping the future of patient care and giving clinicians new ways to improve outcomes.
Topics Covered:
Dry Eye Is More Than a Lack of Tears
One of Dr. Periman’s key messages is that dry eye should not be treated as a single condition. Instead, it represents multiple disease processes that may include inflammation, meibomian gland dysfunction, neurosensory compromise, blepharitis, Demodex, ocular surface pain, and other contributing factors. Successful treatment begins by identifying the underlying mechanisms affecting each individual patient rather than applying the same therapy to everyone.
The Future Is Precision and Molecular Medicine
Perhaps the most exciting advancement is the shift toward highly targeted therapies. Emerging treatments are designed to repair damaged corneal tissue, regulate cellular communication, and reduce pain signaling at the molecular level. Rather than simply managing symptoms, these innovations aim to address the root causes of ocular surface disease and close treatment gaps for patients who have historically had limited options.
Customize Treatment for Every Patient
Dr. Periman encourages clinicians to think in “mechanistic buckets.” Instead of asking whether a patient simply has dry eye, practitioners should determine whether inflammation, rosacea, incomplete blinking, dysbiosis, Demodex, or neurosensory dysfunction is driving symptoms. Matching the right therapy to the right mechanism creates a truly personalized treatment plan and improves long-term outcomes.
The Bottom Line
The future of dry eye disease lies in precision medicine, scientific curiosity, and continuous learning. As new technologies and therapies emerge, eye care professionals have an opportunity to move beyond symptom management and deliver individualized care that meaningfully improves patients’ quality of life. The clinicians who embrace innovation today will help define the next generation of ocular surface disease management.
